Please assess the completion status of the following clinical trial:

Trial Title: MSCs in COVID-19 ARDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* 18 years or older~* Patient has SARS-CoV-2 (COVID-19) confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR) assay or other diagnostic test~* Patient requiring mechanical ventilatory support with moderate to severe ARDS as determined by the following criteria (adapted from the Berlin criteria)~  * Bilateral opacities must be present on a chest radiograph or computerized tomographic (CT) scan. These opacities are not fully explained by pleural effusions, lobar collapse, lung collapse, or pulmonary nodules.~ * Respiratory failure not fully explained by cardiac failure or fluid overload.~ * Moderate to severe impairment of oxygenation must be present, as defined by the ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2). The severity of the hypoxemia defines the severity of the ARDS:~* Moderate ARDS: PaO2/FiO2 \>100 mmHg and ≤200 mmHg, on ventilator settings that include PEEP ≥5 cm H2O OR~* Severe ARDS: PaO2/FiO2 ≤100 mmHg on ventilator settings that include PEEP ≥5 cm H2O~* High sensitivity C-Reactive Protein (hs-CRP) or CRP serum level \>4.0 mg/dL~* Acute Physiologic and Chronic Health Evaluation (APACHE IV) score \>5~* Creatinine clearance of ≥ 30 mL/minute OR a creatinine clearance of 20-29 mL/minute with urine output of ≥0.3 mLs/kg/hour over the last 8 hours or ≥500 mLs over the last 24 hours~* The patient or his/her legally authorized representative (LAR) is able to provide informed consent~Exclusion Criteria~* Currently receiving extracorporeal membrane oxygenation (ECMO) or high frequency oscillatory ventilation (HFOV)~* Females who are pregnant or lactating~* Patients with established positive bacterial blood cultures prior to enrollment or suspicion of superimposed bacterial pneumonia~* Patients with BMI \>55~* Patients with untreated HIV infection~* Patients with malignancy who are within 12 months of active treatment with any chemotherapy, radiation or immunotherapy.~* Patients who have been intubated for more than 72 hours in total at the time of randomization~* Creatinine clearance less than 20 mL/minute or receiving renal replacement therapy~* LFTs (isolated ALT or AST) \> 8x upper limit of normal or \> 5x upper limit of normal in the setting of other liver function abnormalities (i.e., total bilirubin ≥ 2x upper limit of normal)~* Known hypersensitivity to DMSO or to porcine or bovine proteins~* History of prior respiratory disease with requirement for supplemental oxygen~* Any end-stage organ disease which in the opinion of the investigator may possibly affect the safety of remestemcel-L treatment~* Receiving an investigational cellular therapy agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Remestemcel-L Plus Standard of Care (Type: EXPERIMENTAL): Intravenous infusion of remestemcel-L 2x10\^6 MSC/kg of body weight plus standard of care
- Placebo Plus Standard of Care (Type: PLACEBO_COMPARATOR): Placebo (Plasma-Lyte) plus standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).